Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21849260 | 0.79 | — | — | |
| SCHEMBL21893425 | 0.79 | MPO (0.36) | MPOKCNH2LRRK2DGAT1TLR8 | |
| SCHEMBL21848993 | 0.77 | HCRTR1 (0.37) | LRRK2 | |
| SCHEMBL25018461 | 0.75 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL18049627 | 0.75 | MPO (0.39) | MPOKCNH2LRRK2DGAT1IRAK4 | |
| SCHEMBL17173659 | 0.73 | DRD2 (0.30) | — | |
| SCHEMBL21205528 | 0.72 | DGAT1 (0.41) | MPOKCNH2LRRK2DGAT1TLR8 | |
| SCHEMBL25018462 | 0.72 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL802249 | 0.72 | GAA (0.39) | LRRK2IDH1 | |
| SCHEMBL12984693 | 0.71 | MPO (0.40) | MPOKCNH2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MPO 538/4885KCNH2 2603/4885LRRK2 493/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MPO 538/4885KCNH2 2603/4885LRRK2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.